-
公开(公告)号：US20200095557A1
公开(公告)日：2020-03-26
申请号：US16580954
申请日：2019-09-24
Inventor： Nicanor I. Moldovan , Mervin C. Yoder , Nutan Prasain
Abstract: Co-culture of isolated human induced pluripotent stem cell (iPSC)-derived endothelial and smooth-muscle progenitor cells results in the formation of cellular spheroids having capillary-like structures (referred to herein as ‘capillary fragments’) at their core. Bioprinting of these spheroids into scaffold-free tissue constructs facilitates the development of microvasculature within the engineered tissue. Methods of using these bioprinted engineered tissues for cell therapy are also disclosed.
-
2.发明申请公开(公告)号：US20160115454A1
公开(公告)日：2016-04-28
申请号：US14928383
申请日：2015-10-30
Inventor： Mervin C. Yoder , David A. Ingram
IPC: C12N5/071 , G01N33/569 , G01N33/50 , C12N5/0789
Abstract: A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
Abstract translation: 从哺乳动物脐带血，脐静脉和主动脉鉴定了内皮细胞集落形成细胞（EPCs）的层次。 分离并鉴定了称为高增殖潜力 - 内皮细胞集落形成细胞（HPP-ECFC）的新分离的细胞。 开发了单细胞测定法，其测试来自脐带血或来自HUVEC和HAEC的内皮细胞的增殖和克隆潜能。 发现EPCs存在血管壁。 使用源自人类脐带血的来自高增殖潜能 - 内皮细胞集落形成细胞（HPP-ECPCS）的细胞饲养层，刺激再造血造血干细胞和祖细胞的生长和存活。 通过在体外培养物中增加祖细胞数量和NOD / SCID免疫小鼠移植系统中人细胞移植水平的增加来确定刺激生长和存活。
-
3.发明授权公开(公告)号：US10828337B2
公开(公告)日：2020-11-10
申请号：US15891252
申请日：2018-02-07
Inventor： Mervin C. Yoder , Paul Critser , Sherry Voytik-Harbin
Abstract: Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior.
-
4.发明申请公开(公告)号：US20190000891A1
公开(公告)日：2019-01-03
申请号：US15891252
申请日：2018-02-07
Inventor： Mervin C. Yoder , Paul Critser , Sherry Voytik-Harbin
CPC classification number: A61K35/51 , A61K9/70 , A61L27/24 , A61L27/3808
Abstract: Materials and methods are disclosed for controlling vasculogenesis using building blocks of a collagen matrix and endothelial colony forming cells (ECFC). The building blocks may be isolated by fractionating an acid soluble Type I collagen. The building blocks comprising monomers and/or oligomers may be recombined in desired ratios to alter the matrix microenvironment and to influence ECFC behavior.
-
公开(公告)号：US11739293B2
公开(公告)日：2023-08-29
申请号：US16323722
申请日：2017-08-04
Inventor： Mervin C. Yoder , Nutan Prasain
IPC: C12N5/0735 , C12N5/071 , A61K35/12
CPC classification number: C12N5/0606 , A61K35/12 , C12N5/069 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/65 , C12N2506/02 , C12N2506/03 , C12N2506/45 , C12N2533/54
Abstract: The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent stem cells into KDR+NCAM+APLNR+ mesoderm cells and/or SSEA5−KDR+NCAM+APLNR+ mesoderm cells is provided. The disclosed mesoderm cells may be used to generate blood vessels in vivo and/or further differentiated in vitro into endothelial colony forming cell-like cells (ECFC-like cells). Purified human cell populations of KDR+NCAM+APLNR+ mesoderm cells and ECFC-like cells are provided. Test agent screening and therapeutic methods for using the cell populations of the present disclosure are provided.
-
Patent Agency Ranking
公开(公告)号：US20190388477A1
公开(公告)日：2019-12-26
申请号：US16311633
申请日：2018-02-21
Inventor： Mervin C. Yoder , David P. Basile
Abstract: The present disclosure provides compositions and methods for the treatment or prophylaxis of a perfusion disorder, such as ischemia and/or reperfusion injury, in a subject's organ, tissue or extremity by preserving or improving endothelial function, reducing vascular injury, and/or promoting vascular repair. The disclosed compositions comprise endothelial colony-forming cells or a serum-free composition comprising chemically defined media conditioned by endothelial colony-forming cells.
-
公开(公告)号：US20180305661A1
公开(公告)日：2018-10-25
申请号：US16020286
申请日：2018-06-27
Inventor： Mervin C. Yoder , David A. Ingram
IPC: C12N5/00 , C12N5/0789 , C12N5/071 , G01N33/569 , G01N33/50 , A61K35/12
CPC classification number: C12N5/0068 , A61K2035/124 , C12N5/0647 , C12N5/0692 , C12N2501/125 , C12N2501/145 , C12N2501/22 , C12N2501/26 , C12N2502/28 , C12N2533/54 , C12N2533/90 , G01N33/5005 , G01N33/56966 , G01N2333/70589 , G01N2333/70596
Abstract: A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
-
8.发明申请公开(公告)号：US20190211304A1
公开(公告)日：2019-07-11
申请号：US16323722
申请日：2017-08-04
Inventor： Mervin C. Yoder , Nutan Prasain
IPC: C12N5/0735 , A61K35/12
CPC classification number: C12N5/0606 , A61K35/12 , C12N5/069 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/65 , C12N2506/02 , C12N2506/03 , C12N2506/45 , C12N2533/54
Abstract: The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent stem cells into KDR+NCAM+APLNR+ mesoderm cells and/or SSEA5−KDR+NCAM+APLNR+ mesoderm cells is provided. The disclosed mesoderm cells may be used to generate blood vessels in vivo and/or further differentiated in vitro into endothelial colony forming cell-like cells (ECFC-like cells). Purified human cell populations of KDR+NCAM+APLNR+mesoderm cells and ECFC-like cells are provided. Test agent screening and therapeutic methods for using the cell populations of the present disclosure are provided.
-
公开(公告)号：US10041036B2
公开(公告)日：2018-08-07
申请号：US14985908
申请日：2015-12-31
Inventor： Mervin C. Yoder , David A. Ingram
IPC: C12N5/00 , C12N5/0789 , C12N5/071 , G01N33/50 , G01N33/569 , A61K35/12
Abstract: A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential-endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
-
10.发明申请公开(公告)号：US20160168533A1
公开(公告)日：2016-06-16
申请号：US14985908
申请日：2015-12-31
Inventor： Mervin C. Yoder , David A. Ingram
IPC: C12N5/00 , C12N5/071 , G01N33/569
CPC classification number: C12N5/0068 , A61K2035/124 , C12N5/0647 , C12N5/0692 , C12N2501/125 , C12N2501/145 , C12N2501/22 , C12N2501/26 , C12N2502/28 , C12N2533/54 , C12N2533/90 , G01N33/5005 , G01N33/56966 , G01N2333/70589 , G01N2333/70596
Abstract: A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential-endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.
Abstract translation: 从哺乳动物脐带血，脐静脉和主动脉鉴定了内皮细胞集落形成细胞（EPCs）的层次。 分离并鉴定了称为高增殖潜力 - 内皮细胞集落形成细胞（HPP-ECFC）的新分离的细胞。 开发了单细胞测定法，其测试来自脐带血或来自HUVEC和HAEC的内皮细胞的增殖和克隆潜能。 发现EPCs存在血管壁。 使用源自人类脐带血的高增殖潜能 - 内皮细胞集落形成细胞（HPP-ECPCS）的细胞饲养层，刺激再造血造血干细胞和祖细胞的生长和存活。 通过在体外培养物中增加祖细胞数量和NOD / SCID免疫小鼠移植系统中人细胞移植水平的增加来确定刺激生长和存活。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.018 seconds)
